Patent details

300974 Product Name: Binimetinib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout of solvaat

The time of generation of the report may vary depending on the number of the selected files and the pages of each file. If the generation of the consolidated PDF file takes long, you may reduce the number of selected files and proceed with the generation of the PDF in batches.
You have not selected any documents

Basic Information

Publication number:
300974
Type:
Certificate
SPC Type:
Medical
Basic Patent Number:
EP1482932
Status:
SPC in force
Application number:
300974
Procedural language:
Dutch
First Applicant Residence Country:
United States of America (US)

Marketing Authorization

Marketing Authorization Number:
EU/1/18/1315
Marketing Authorization Type:
EEA
Marketing Authorization Date:
24/09/2018
Marketing Authorization Country:
European Union (EU)

Dates

Filing date:
15/03/2019
First Marketing Authorization date:
24/09/2018
Grant date:
06/04/2022
Activation date:
13/03/2023
Lapsed By Non Payment Annual Fee Date:
Renunciation Date:
NullificationDate:
Registration date:
21/03/2019
SPC/SPC Extension Expiration Date:
12/03/2028
Lapsed By Expiration Date:
Withdrawal date:
Revocation Date:
Invalidity Date:
Withdrawal Market Authorization Date:
Refusal Date:

Applicant/holder

From:
28/06/2019
 
 

 

Name:
AstraZeneca AB
Address:
Västra Mälarehamnen 9, 15185, Södertälje, Sweden (SE)

From:
28/06/2019
 
 

 

Name:
Array BioPharma Inc.
Address:
3200 Walnut Street, 80301, Boulder, CO, United States of America (US)

Historical Applicant/holder

From:
15/03/2019
To:
28/06/2019

 

Name:
Array Biopharma, Inc.
Address:
3200 Walnut Street, 80301, Boulder, Colorado, United States of America (US)

From:
15/03/2019
To:
28/06/2019

 

Name:
AstraZeneca AB
Address:
Västra Mälarehamnen 9, 15185, Södertälje, Sweden (SE)

Agent

1

Name:
ir. B.Ch. Ledeboer c.s
From:
28/07/2025
Address:
V.O. Postbus 87930, 2508 DH, Den Haag, Netherlands (NL)
To:

2

Name:
ir. H.A. Witmans c.s.
From:
15/03/2019
Address:
V.O. Postbus 87930, 2508 DH, Den Haag, Netherlands (NL)
To:
28/07/2025

Publication

Bulletin

1

Bulletin Heading:
SPC
Journal edition number:
11/23
Publication date:
15/03/2023
Description:
Applications and granted Supplementary Protection Certificates (or the extensions of the Supplementary Protection Certificates)

2

Bulletin Heading:
SPC
Journal edition number:
14/22
Publication date:
06/04/2022
Description:
Applications and granted Supplementary Protection Certificates (or the extensions of the Supplementary Protection Certificates)

3

Bulletin Heading:
CO
Journal edition number:
28/19
Publication date:
10/07/2019
Description:
Changes in the Netherlands Patent Register

4

Bulletin Heading:
SPC
Journal edition number:
13/19
Publication date:
27/03/2019
Description:
Applications and granted Supplementary Protection Certificates (or the extensions of the Supplementary Protection Certificates)

Deed

Change of owner(s)

Change Kind/ Decision Type:
Change of owner(s) name
Deed Number:
RC201901285B
Date Registered:
28/06/2019
License Effective Date:
License Expiration Date:
Scope of License:
Deed Filer:
ir. H.A. Witmans c.s.
Journal Edition Number:
Text:
Deed Status:
Country Code:
Updated License Number:
Terminated License Number:

Added Owner(s)

1

Name:
AstraZeneca AB
Address:
Västra Mälarehamnen 9, 15185, Södertälje, Sweden (SE)

2

Name:
Array BioPharma Inc.
Address:
3200 Walnut Street, 80301, Boulder, CO, United States of America (US)

Changed Pledgee

Name:
Address:

Removed Usufructuary

Name:
Address:

Added Usufructuary

Name:
Address:

Changed Usufructuary

Name:
Address:

Annual Fee

Annual Fee(s) Due Date:
31/03/2026
Annual Fee Number:
24
Annual Fee Amount:
2200 Euro
Last Annual Payment Date:
20/12/2024
Last Annual Fee Paid Number:
23
Last Annual Fee Paid Amount:
2000 Euro
Payer:
Master Data Center
Filing date Document type Document Description Number of pages File Type
06/04/2022 Outgoing Correspondence Decision grant 1 PDF /4/0/4/8/8/0800388404/docs/300974_9_472475l504a.pdf
06/04/2022 Certificate Certificate 1 PDF /4/0/4/8/8/0800388404/docs/300974_10_spcmedcertificate20220406085142961.pdf
25/03/2022 Incoming Correspondence Paper Incoming Correspondence Paper 2 PDF /4/0/4/8/8/0800388404/docs/300974_0_incomingcorrespondencepaper20220325035739590.pdf
12/01/2022 Outgoing Correspondence Letter to applicant 2 PDF /4/0/4/8/8/0800388404/docs/300974_4_455605l173.pdf
21/03/2019 Outgoing Correspondence Confirmation receipt request 1 PDF /4/0/4/8/8/0800388404/docs/300974_8_260746l174.pdf
15/03/2019 SPC Documents Marketing Authorization SPC 3 PDF /4/0/4/8/8/0800388404/docs/300974_1_supplprotectioncertificate20190320034727765.pdf
15/03/2019 SPC Documents Summary of the characteristics of the product 27 PDF /4/0/4/8/8/0800388404/docs/300974_2_supplprotectioncertificate20190320034727833.pdf
15/03/2019 SPC Documents Annex SPC 14 PDF /4/0/4/8/8/0800388404/docs/300974_3_supplprotectioncertificate20190320034727954.pdf
15/03/2019 Application Form First filed application form 3 PDF /4/0/4/8/8/0800388404/docs/300974_5_applicationform20190320034727555.pdf
15/03/2019 SPC Documents Accompanying letter SPC 1 PDF /4/0/4/8/8/0800388404/docs/300974_6_supplprotectioncertificate20200602040025596.pdf
15/03/2019 SPC Documents Annex SPC 2 PDF /4/0/4/8/8/0800388404/docs/300974_7_supplprotectioncertificate20190320034727892.pdf